Amedisys Inc (NASDAQ:AMED) has been assigned a $50.00 price target by investment analysts at Jefferies Group in a report issued on Friday. The brokerage currently has a “buy” rating on the stock. Jefferies Group’s price objective suggests a potential upside of 15.21% from the company’s current price.

Other equities research analysts have also recently issued reports about the company. Mizuho upgraded Amedisys from a “neutral” rating to a “buy” rating and set a $47.00 target price on the stock in a research note on Monday, November 7th. Craig Hallum assumed coverage on Amedisys in a report on Friday, December 16th. They set a “buy” rating and a $48.00 price target on the stock. Finally, Zacks Investment Research raised Amedisys from a “sell” rating to a “hold” rating in a report on Monday. Five investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Amedisys currently has an average rating of “Hold” and an average price target of $50.00.

Analyst Recommendations for Amedisys (NASDAQ:AMED)

Amedisys (NASDAQ:AMED) traded up 0.85% during midday trading on Friday, hitting $43.77. 56,796 shares of the company traded hands. The stock has a 50 day moving average of $41.66 and a 200 day moving average of $46.34. Amedisys has a 12-month low of $31.16 and a 12-month high of $55.16. The stock has a market cap of $1.47 billion, a P/E ratio of 35.70 and a beta of 1.35.

Amedisys (NASDAQ:AMED) last posted its earnings results on Thursday, November 3rd. The company reported $0.36 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.44 by $0.08. The company earned $361.60 million during the quarter, compared to the consensus estimate of $361.08 million. Amedisys had a net margin of 2.93% and a return on equity of 11.94%. The business’s quarterly revenue was up 10.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.34 earnings per share. Equities research analysts predict that Amedisys will post $1.49 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This news story was originally published by Watch List News and is the propert of of Watch List News. If you are viewing this news story on another website, it was illegally copied and reposted in violation of United States and international copyright law. The legal version of this news story can be viewed at http://www.watchlistnews.com/amedisys-inc-amed-given-a-50-00-price-target-by-jefferies-group-analysts/1060181.html.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. New York State Teachers Retirement System raised its position in Amedisys by 11.2% in the second quarter. New York State Teachers Retirement System now owns 79,311 shares of the company’s stock worth $4,004,000 after buying an additional 8,000 shares during the last quarter. Boston Advisors LLC raised its position in Amedisys by 52.5% in the second quarter. Boston Advisors LLC now owns 36,687 shares of the company’s stock worth $1,852,000 after buying an additional 12,624 shares during the last quarter. Swiss National Bank raised its position in Amedisys by 7.1% in the second quarter. Swiss National Bank now owns 46,700 shares of the company’s stock worth $2,357,000 after buying an additional 3,100 shares during the last quarter. First Trust Advisors LP raised its position in Amedisys by 37.6% in the second quarter. First Trust Advisors LP now owns 44,721 shares of the company’s stock worth $2,258,000 after buying an additional 12,227 shares during the last quarter. Finally, Sheaff Brock Investment Advisors LLC purchased a new position in Amedisys during the second quarter worth about $1,058,000. 93.52% of the stock is currently owned by hedge funds and other institutional investors.

About Amedisys

Amedisys, Inc (Amedisys) is a provider of home health and hospice services. The Company offers home health services to the chronic, co-morbid, aging American population. The Company operates through three segments: home health, hospice and personal care. The Company’s home health segment delivers a range of services in the homes of individuals recovering from surgery, have a chronic disability or terminal illness or need assistance with completing important personal tasks.

5 Day Chart for NASDAQ:AMED

Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.